Cervical cancer screening and treatment costing in Senegal.


Journal

The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926

Informations de publication

Date de publication:
2024
Historique:
received: 21 08 2023
accepted: 17 01 2024
medline: 8 7 2024
pubmed: 8 7 2024
entrez: 8 7 2024
Statut: epublish

Résumé

in Senegal, cervical cancer is the leading cause of cancers among women. This study estimated the costs associated with cervical cancer screening and treatment for precancerous lesions from the health system perspective. we estimated costs for screening, diagnostics, and treatment. We conducted a cross-sectional study in seven regions with primary data collected from 50 health facilities. Data collection included structured questionnaires, with secondary data from the Ministry of Health and other sources. A mixed-methods approach combined ingredients-based costing and financial expenditures to estimate direct medical and non-medical costs. All costs are reported in 2019 USD. average costs were $3.71 for visual inspection with acetic acid, $16.49 for Pap smear, and $46.65 for human papillomavirus deoxyribonucleic acid (HPV DNA) testing. Screening cost drivers were clinical exam supplies and clinical equipment for visual inspection with acetic acid, offsite processing of specimens for Pap smear, and lab equipment costs for HPV DNA procedure. The average cost of diagnosis via colposcopy alone was $25.73, and colposcopy with biopsy/endocervical curettage was $74.96. The average cost of treatment followed by one visit for pre-cancerous lesions was $195.24 for loop electrosurgical excision, $47.35 for cryotherapy, and $32.35 for thermal ablation. Clinical equipment and lab costs were the largest contributors to colposcopy and endocervical curettage/biopsy expenses. Clinical equipment made up the largest portion of cryotherapy, loop electrosurgical excision, and thermoablation costs. this study is the first to estimate the costs of HPV screening and treatment in Senegal, which can be used to inform decision-making on cervical cancer investments.

Identifiants

pubmed: 38974700
doi: 10.11604/pamj.2024.47.151.41485
pii: PAMJ-47-151
pmc: PMC11226758
doi:

Substances chimiques

Acetic Acid Q40Q9N063P

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

151

Informations de copyright

Copyright: Abdou Diop et al.

Déclaration de conflit d'intérêts

The authors declare no competing interests.

Auteurs

Abdou Diop (A)

Center for Vaccine Innovation and Access, PATH, Dakar, Senegal.

Mercy Mvundura (M)

Product and Market Advancement, PATH, Seattle, USA.

Yacine Dieng (Y)

Cancer Focal Point, Non-Communicable Disease Division, Ministry of Health and Social Action, Dakar, Senegal.

Malick Anne (M)

Non-Communicable Disease Division, Ministry of Health and Social Action, Dakar, Senegal.

Elisabeth Vodicka (E)

Center for Vaccine Innovation and Access, PATH, Seattle, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH